Clinical Trial Detail

NCT ID NCT01801163
Title A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Indiana University
Indications

hepatocellular carcinoma

Therapies

Sorafenib

Age Groups: adult

No variant requirements are available.